Fig. 3From: Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degenerationGraph showing difference in area of macular atrophy (mean ± SD) between ranibizumab and aflibercept treatment groups at the end of follow-up. Difference between groups was statistically not significant (p = 0,4708)Back to article page